THE BLOOD FACTOR
-
BEYOND-9 hemophilia B gene therapy clinical trial launched in four Canadian study sites
Montreal, February 5, 2026 – Four Canadian bleeding disorder treatment centres are participating in the Phase 1 clinical trial of Regeneron’s CRISPR/Cas9-based targeted gene insertion...
-
The CHS pressures provinces to reimburse hemophilia B gene therapy
Montréal, December 17, 2025 – The Canadian Hemophilia Society (CHS) has written to the Provincial/Territorial Ministers of Health (excluding Quebec) to urge them to add...
-
The CHS urges provinces to accept CBS recommendation to introduce Altuviiio
Montréal, December 12, 2025 – In a letter dated December 10, the Canadian Hemophilia Society (CHS) urged the Provincial/Territorial Blood Liaison Committee (P/TBLC) to accept...
-
Gene therapy for hemophilia B one step closer: CSL Behring and pCPA agree on pricing
MONTREAL, October 7, 2025 – CSL Behring Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have announced signing of a Letter of Intent that sets pricing...
-
Update on novel therapies for hemophilia A and B
MONTRÉAL, September 19, 2025 – No announcements have been made over the summer on progress in gaining access to two novel hemophilia therapies. Altuviiio for...